Exit

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Columbia’s Text IQ has been bought by Relativity for an undisclosed amount.

Lund spinout Glō has agreed to an acquisition by Nanosys, which will now look to strengthen its market share in TV sets and enter more markets such as AR.

IP Group is exiting the diffractive waveguide producer in a cash-and-share purchase by Snap.

The Lund research-based oat milk brand has floated in a $1.43bn IPO on the Nasdaq Global Select Market after pricing shares at $17.

SUNY Polytechnic University-backed Norsk Titanium has begun trading on Euronext Growth Oslo.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.